Literature DB >> 15102353

Genes causing inherited cancer as beacons to identify the mechanisms of chemoresistance.

Per Eystein Lønning1.   

Abstract

Mechanisms of resistance to cancer chemotherapy are poorly understood. Molecular pathways involving genes associated with inherited cancer syndromes could represent mechanisms of chemoresistance. Microarray techniques can identify simultaneous alterations in the mRNA expression of multiple genes, but identification of the exact mechanism responsible for a particular phenotype, including resistance to a specific drug, remains problematic. Genes in which mutations cause inherited cancers play vital roles in apoptosis, growth arrest and/or DNA repair, and are inactivated by somatic mutations, deletions or hypermethylation in most cancer tissues. Similarities between carcinogenic injury and cell damage created by chemotherapeutics suggests that somatic inactivation of such genes is crucially important to drug sensitivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102353     DOI: 10.1016/j.molmed.2004.01.005

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  19 in total

Review 1.  Molecular basis for therapy resistance.

Authors:  Per E Lønning
Journal:  Mol Oncol       Date:  2010-04-24       Impact factor: 6.603

2.  A literature mining-based approach for identification of cellular pathways associated with chemoresistance in cancer.

Authors:  Jung Hun Oh; Joseph O Deasy
Journal:  Brief Bioinform       Date:  2015-07-27       Impact factor: 11.622

3.  Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma.

Authors:  Thomas Clozel; ShaoNing Yang; Rebecca L Elstrom; Wayne Tam; Peter Martin; Matthias Kormaksson; Samprit Banerjee; Aparna Vasanthakumar; Biljana Culjkovic; David W Scott; Sarah Wyman; Micheal Leser; Rita Shaknovich; Amy Chadburn; Fabrizio Tabbo; Lucy A Godley; Randy D Gascoyne; Katherine L Borden; Giorgio Inghirami; John P Leonard; Ari Melnick; Leandro Cerchietti
Journal:  Cancer Discov       Date:  2013-08-16       Impact factor: 39.397

Review 4.  Exosomes-mediate microRNAs transfer in breast cancer chemoresistance regulation.

Authors:  Juliana Carvalho Santos; Marcelo Lima Ribeiro; Luis Otávio Sarian; Manoela Marques Ortega; Sophie Françoise Derchain
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

Review 5.  Effect of NF-κB inhibition on chemoresistance in biliary-pancreatic cancer.

Authors:  Tadashi Uwagawa; Katsuhiko Yanaga
Journal:  Surg Today       Date:  2015-02-12       Impact factor: 2.549

6.  Identification and characterization of retinoblastoma gene mutations disturbing apoptosis in human breast cancers.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Stephanie Geisler; Vidar Staalesen; Marec Pacal; Anne-Lise Børresen-Dale; Pål Puntervoll; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Mol Cancer       Date:  2010-07-01       Impact factor: 27.401

7.  Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Authors:  Stian Knappskog; Ranjan Chrisanthar; Erik Løkkevik; Gun Anker; Bjørn Østenstad; Steinar Lundgren; Terje Risberg; Ingvil Mjaaland; Beryl Leirvaag; Hrvoje Miletic; Per E Lønning
Journal:  Breast Cancer Res       Date:  2012-03-15       Impact factor: 6.466

8.  Alterations of the retinoblastoma gene in metastatic breast cancer.

Authors:  Elisabet Ognedal Berge; Stian Knappskog; Johan Richard Lillehaug; Per Eystein Lønning
Journal:  Clin Exp Metastasis       Date:  2011-01-21       Impact factor: 5.150

9.  Strength and weakness of phase I to IV trials, with an emphasis on translational aspects.

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2008-12-18       Impact factor: 6.466

10.  Tailored targeted therapy for all: a realistic and worthwhile objective?

Authors:  Per Eystein Lønning
Journal:  Breast Cancer Res       Date:  2009-12-18       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.